Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

From Bugs to Brains: the gut microbiome in neurological health
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
Multiple sclerosis in pregnancy.
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
SigmaPharm Laboratories Products
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients.
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Risks of immune system treatments.
Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo.
Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Oligodendroglial membrane dynamics in relation to myelin biogenesis.
The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.

Pages